In an effort to marry T cell and natural killer cell technologies for the treatment of blood cancer, Dutch biotech Kiadis has inked an all-stock deal to acquire US-based CytoSen Therapeutics. Both companies have had the same goal: to boost the chances of cancer patients undergoing hematopoietic stem cell transplants by supercharging their immune system … Continue reading T cell experts at Kiadis bag CytoSen’s NK cell tech, plotting a dual cancer killing approach with tips from Carl June